Institutional members access full text with Ovid®

Share this article on:

Is Extracorporeal CO2 Removal Really “Safe” and “Less” Invasive? Observation of Blood Injury and Coagulation Impairment during ECCO2R

Kalbhenn, Johannes*; Neuffer, Nadine*; Zieger, Barbara; Schmutz, Axel*

doi: 10.1097/MAT.0000000000000544
Pulmonary

Extracorporeal CO2 removal (ECCO2R) is promoted with attributes like “safe” and “less invasive” compared with (high-flow) venovenous extracorporeal membrane oxygenation (ECMO) systems. With our experience in coagulation disorders during ECMO therapy with this observational study, we for the first time prospectively evaluate hemolysis and coagulation disorders during ECCO2R. Eight consecutive patients with predominant hypercapnic respiratory failure were treated with the Hemolung respiratory assist system (Alung-Technologies, Pittsburg, PA). Bleeding as well as changes of coagulation parameters was prospectively assessed. Overall therapy was observed in seven patients with 52 treatment days. In four of seven patients (57%), relevant clinical bleeding symptoms occurred. Thrombocytopenia, hemolysis, factor XIII deficiency and acquired von Willebrand syndrome (loss of high-molecular-weight von Willebrand factor multimers) were typical findings, and the patients spontaneously recovered after discontinuation of the extracorporeal system. In one patient, extracorporeal system stopped because of thrombotic occlusion. Six of seven patients required transfusion of red blood cells. Our observation shows that even low-flow extracorporeal lung support is associated with relevant clinical bleeding symptoms, blood cell injury, development of acquired von Willebrand syndrome and need for transfusion. In our opinion, it therefore is too early to quote ECCO2R “safe” and “less invasive.”

From the *Department of Anesthesiology and Critical Care and Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center – Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.

Submitted for consideration August 2016; accepted for publication in revised form January 2017.

Disclosure: Dr. Kalbhenn received speaker fees from Alung Technologies in 2013. Laboratory costs were financed by departmental funding. Hemolung RAS disposals in the first five patients were provided by ALung Technologies Inc., Pittsburg, PA.

Correspondence: Johannes Kalbhenn, Hugstetter Strasse 55, 79106 Freiburg, Germany. Email: Johannes.kalbhenn@uniklinik-freiburg.de.

Copyright © 2017 by the American Society for Artificial Internal Organs